China News Agency, Beijing, June 5 (Reporter Li Yanan) China National Medical Security Bureau issued the "Guiding Opinions on the Establishment of Pharmaceutical Prices and Recruitment Credit Evaluation System (Second Consultation Draft)" on the 5th, which proposed the establishment of pharmaceutical prices And recruited a list of catalogues of untrustworthy items, carried out credit rating of pharmaceutical companies, and handled breach of contract breaches in different stages, including suspension of the qualifications of unsuccessful companies for delivery of winning drugs or medical consumables, and public disclosure of breach of trust information to the public.
At present, commercial bribery and market manipulation in the pharmaceutical field have caused the prices of medicines and medical consumables to be artificially high, medical expenses to grow too fast, and large losses of medical insurance funds, which have seriously endangered the safety of medical insurance funds.
The National Medical Insurance Bureau pointed out that in order to improve the market-led pharmaceutical price formation mechanism and establish a pharmaceutical price and recruitment credit evaluation system, the guidance relies on the bidding and procurement platform for pharmaceuticals and medical consumables, system integration of trustworthy commitments, credit ratings, graded disposal, Mechanisms such as credit repairs, and the establishment of a pharmaceutical evaluation system with equal rights and responsibilities, coordinated and coordinated medical prices and bidding procurement, to protect the interests of the people and the safety of medical insurance funds.
The Guiding Opinions propose to establish a list of pharmaceutical prices and catalogues of untrustworthy matters, including but not limited to pharmaceutical commercial bribery, abuse of market dominance, manipulation of market prices, violation of contractual agreements, disruption of procurement orders, and other violations of laws and regulations, contrary to integrity and fairness Competitive behavior. In the process of pricing, bidding, performance, and marketing, pharmaceutical companies that engage in unfair competition and obtain illegitimate benefits through the actions listed in the catalogue will be included in the scope of the evaluation of pharmaceutical prices and credit evaluation of bidding and procurement.
According to the guidance, a combination of enterprise reports and platform records will be used to establish a price database for pharmaceutical companies' price recruitment and untrustworthiness. The reputation of pharmaceutical companies in the local bidding and procurement market was rated as four levels: general, medium, severe, and particularly serious. With regard to untrustworthy conduct such as pharmaceutical commercial bribery, the facts on which the credit rating is based shall be subject to the court’s judgment or the administrative penalty decision of the law enforcement department.
At the same time, the breach of contract will be dealt with in a hierarchical manner. According to the credit rating of the pharmaceutical company, the centralized purchasing agency shall take written reminders and warnings, prompt the buyer of risk information, suspend the bidding of the company’s related drugs or medical consumables, suspend the company’s qualification to distribute the winning drugs or medical consumables, and publicly disclose to the public Disposal measures such as untrustworthy information.
The National Medical Insurance Bureau said that the establishment of a pharmaceutical price and recruitment credit evaluation system is an important measure to purify the order of the pharmaceutical market and promote the high-quality development of the pharmaceutical industry. In the future, medical institutions will be guided to preferentially select pharmaceutical companies with better credit ratings as supply or distribution units under the same conditions. (Finish)